Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott: Q2 Earnings Snapshot

07/22/2021 | 07:27am EDT

ABBOTT PARK, Ill. (AP) _ Abbott Laboratories (ABT) on Thursday reported second-quarter profit of $1.19 billion.

On a per-share basis, the Abbott Park, Illinois-based company said it had net income of 66 cents. Earnings, adjusted for one-time gains and costs, came to $1.17 per share.

The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.01 per share.

The maker of infant formula, medical devices and drugs posted revenue of $10.22 billion in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $9.72 billion.

Abbott expects full-year earnings in the range of $4.30 to $4.50 per share.

Abbott shares have increased almost 9% since the beginning of the year, while the S&P's 500 index has increased 16%. The stock has climbed 21% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ABT at https://www.zacks.com/ap/ABT

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about ABBOTT LABORATORIES
09/23ABBOTT : Hosts Conference Call for Third-Quarter Earnings
PR
09/20GLOBAL MARKETS LIVE : Universal Music Group, China Evergrande, ENI, Prudential, Microsoft...
09/20ABBOTT LABORATORIES : Gets FDA Clearance for Portico with FlexNav Transcatheter Aortic Val..
MT
09/20Abbott Receives FDA Approval for Minimally Invasive Portico with FlexNav TAVR System to..
CI
09/15ABBOTT LABORATORIES : to Pay Quarterly Cash Dividend of $0.45 a Share on Nov. 15 to Shareh..
MT
09/15ABBOTT : Declares 391st Consecutive Quarterly Dividend
PR
09/15Abbott Laboratories Declares Quarterly Dividend, Payable on November 15, 2021
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/13INSIDER SELL : Abbott Laboratories
MT
09/10QIAGEN N : 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 39 807 M - -
Net income 2021 5 837 M - -
Net Debt 2021 8 454 M - -
P/E ratio 2021 37,7x
Yield 2021 1,37%
Capitalization 220 B 220 B -
EV / Sales 2021 5,75x
EV / Sales 2022 5,73x
Nbr of Employees 109 000
Free-Float 88,8%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 124,37 $
Average target price 130,04 $
Spread / Average Target 4,56%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES13.59%220 485
MEDTRONIC PLC11.00%174 982
BECTON, DICKINSON AND COMPANY1.18%72 711
HOYA CORPORATION30.69%62 143
ALIGN TECHNOLOGY, INC.35.72%57 302
SARTORIUS STEDIM BIOTECH77.82%55 891